GlobeNewswire by notified

SAB Launch Services awarded contract to launch two ICEYE SAR satellites

Share

The contract signed between ICEYE and SAB Launch Services includes the launch of two SAR satellites on VEGA-C, operated by Arianespace

PARIS, Sept. 20, 2022 (GLOBE NEWSWIRE) -- SAB Launch Services S.r.l., a company part of the SAB group specialized in Small Satellite launch service provision on Arianespace missions, and ICEYE, the global leader in persistent monitoring with radar satellite imaging, have signed an agreement to fly two Synthetic Aperture Radar (SAR) satellites on the first VEGA-C SSMS mission in Q1 2023.

Owning the world’s largest SAR satellite constellation, ICEYE delivers proven and reliable Earth Observation solutions and is the only organization in the world to offer the rapid delivery of high-precision SAR satellites and data to its customers, allowing them to take full control of their mission.

“We are excited to be launching a pair of our SAR satellites in early 2023 and to continuously grow our SAR constellation,” said Aloïs Lepâtre, Launch Manager at ICEYE. “SAB has been extremely supportive of our integration and orbit needs, and we acknowledge the flexibility and ownership we were given by being able to select an orbit that meets our specific requirements.”

“SAB is very proud to announce the signature of this Launch Service agreement which is a big achievement for our company, which can now be recognized also as a Launch Service provider for Microsatellites, in particular for one of the most relevant constellations in the world”, commented Marco Mariani, CEO of SAB Launch Services, during the event organized at IAC. “This agreement shows the appreciation from commercial customers for VEGA Services, including those used to take advantage of Non-European launch services in the past. I think that the service we are able to offer is very peculiar since it leverages on VEGA performance and on the SSMS System. Therefore, we can provide spots in rideshare missions, flying the satellites not-cantilevered, and offering our customers the possibility to select the orbit. I see these three factors as a winning mix, which places our entire organization in a unique position to compete and win on the worldwide launch market. ICEYE is definitely a very important partner and we will do our best to reinforce this cooperation.”

The partnership between SAB and ICEYE highlights the appreciation from commercial customers for the modularity and flexibility provided by the VEGA-C launcher System in combination with the SSMS Dispenser. The two ICEYE spacecraft will be flown on VEGA-C mission VV23, the first flight of the SSMS on the new rocket, which had a successful maiden flight in July.

The two spacecraft will be accommodated in VV23 on the upper part of the SSMS dispenser together with the two main passengers of this mission. The final aggregate counts a total of 5 microsatellites and a large number of deployers including institutional as well commercial cubesats customers from all over the world. Thanks to the AVUM performance, the aggregate will be released in 3 different orbits, whereas one of them has been specifically selected by ICEYE.

About SAB Launch Services

SAB Launch Services S.r.l. (SAB-LS) is a company part of SAB group offering launch services on European Launchers for all kind of Small Satellites. SAB-LS offers “end to end” services including launch procurement, separation system procurement, integration activities of the satellite on the launch vehicle structure, In-Orbit Services, pre- and post-launch support. Due to the flexible and direct access to launch capacity afforded by the SAB-LS partnership with Arianespace, SAB-LS is the key European firm serving Nanosatellite and Microsatellites customers looking to launch on European vehicles.

For more information, visit https://www.sablaunchservices.com/.

Media Contact:

rpatricio@sabls.com

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/8046a014-0c04-4bb4-9546-868feca62026

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

RevoluGROUP Announces CEO and Director Stepping Down3.5.2024 00:25:00 CEST | Press release

VANCOUVER, British Columbia and BARCELONA, Spain., May 02, 2024 (GLOBE NEWSWIRE) -- RevoluGROUP Canada Inc. (TSX- V: REVO), (Frankfurt: IJA2), (Munich: A2PU92) ("RevoluGROUP") today announced CEO and Director, Gavin McMillan, will be stepping down from his positions, effective immediately. Gavin joined the Company in August 2023 and served as CEO for over six months. During his leadership, McMillan has been instrumental in focusing on the continued development of the API-driven Payment-as-a-Service (PaaS) model, which has continued to expand through key white-label partnerships and joint venture agreements and enhancing revenue streams. In a statement, Bernard Lonis, the Chairman of the Board, acknowledged McMillan's vital contributions and leadership, stating, "We owe a great deal of gratitude to Gavin for his dedication and the continued strong foundation he has helpedtobuildforRevoluGROUP'sfuture. We wish Gavin the best in his future endeavors." The Board has commenced a comprehensi

Novotech Appoints Commercial and Clinical Life Sciences Specialist to Head Up Global Drug Development Consulting Team2.5.2024 23:00:15 CEST | Press release

BOSTON, May 02, 2024 (GLOBE NEWSWIRE) -- Novotech, the global full-service clinical Contract Research Organization (CRO) that partners with biotech companies to accelerate the development of advanced and novel therapeutics at every phase, has appointed Scott Schliebner as Vice President and Global Head, Drug Development Consulting (DDC). Novotech’s Chief Medical Officer Dr. Judith Ng-Cashin stated: “We welcome Scott to the medical and scientific team. He is a proven strategic, innovative, and business focused life sciences executive with ~30 year of experience across the biopharma and CRO sectors. He brings valuable leadership to our world-class DDC team, a full-service global drug development and strategic regulatory team providing comprehensive "inception to approval" services.” The DDC partners with biotechs to optimize a fit-for purpose therapeutic development strategy that both advances the development program and creates value for the company. To do this, DDC leverages CMC/manufa

Brookfield Reinsurance Completes Acquisition of AEL2.5.2024 22:10:00 CEST | Press release

BROOKFIELD, NEWS, May 02, 2024 (GLOBE NEWSWIRE) -- Brookfield Reinsurance (NYSE, TSX: BNRE, BNRE.A) and American Equity Investment Life Holding Company (NYSE: AEL) (“AEL”) today announced the completion of Brookfield Reinsurance’s acquisition of AEL in a cash and stock transaction valued at $56.50 per AEL share. AEL’s leading fixed annuity business bolsters Brookfield Reinsurance’s expanding insurance operations and increases its insurance assets under management to over $100 billion. Jon Bayer, Managing Partner at Brookfield Reinsurance said, “We are excited to welcome AEL to our organization as we continue to grow, diversify and scale our retirement services capabilities. AEL’s strong franchise and track record of serving policyholders and distribution partners, coupled with the scale of our existing platform and offerings, will position us well for the next phase of growth.” Brookfield Reinsurance expects to maintain AEL’s headquarters in Des Moines, Iowa, and its growth in the fixe

Fortinet Reports First Quarter 2024 Financial Results2.5.2024 22:05:43 CEST | Press release

First Quarter 2024 Highlights Total revenue of $1.35 billion, up 7% year over yearService revenue of $944 million, up 24% year over yearGAAP operating margin of 23.7%Non-GAAP operating margin of 28.5%1Cash flow from operations of $830 millionFree cash flow of $609 million1 SUNNYVALE, Calif., May 02, 2024 (GLOBE NEWSWIRE) -- Fortinet® (Nasdaq: FTNT), a global cybersecurity leader driving the convergence of networking and security, today announced financial results for the first quarter ended March 31, 2024. “We are diligently executing on our strategy announced six months ago to leverage our scale, go-to-market capabilities, customer-first focus, and engineering expertise to capitalize on the fast-growing Unified SASE and Security Operations markets while continuing to gain market share in Secure Networking,” said Ken Xie, Founder, Chairman and Chief Executive Officer of Fortinet. “We believe our Unified SASE offering is the most comprehensive in the industry and we are well-positioned

Zymeworks Provides Corporate Update and Reports First Quarter 2024 Financial Results2.5.2024 22:05:00 CEST | Press release

Reported $420.5 million in cash resources as of March 31, 2024, which when combined with certain anticipated regulatory milestone payments provides projected cash runway into 2H 2027Completion of rolling biologics license application (BLA) filing with the U.S. Food and Drug Administration (FDA) for zanidatamab as second-line treatment for biliary tract cancers (BTC) in the United States (U.S.) by our partner, Jazz PharmaceuticalsExpected initiation of a Phase 3 clinical trial for zanidatamab in the second half of 2024, for breast cancer patients who have progressed on trastuzumab deruxtecan (T-DXd), by our partner, Jazz Pharmaceuticals Two planned investigational new drug (IND) and foreign equivalent submissions in 2024 for ZW191 and ZW171Acceptance of an abstract for zanidatamab in BTC at the American Society of Clinical Oncology (ASCO) annual meeting submitted by our partner, Jazz PharmaceuticalsPresentation of five abstracts at the American Association for Cancer Research (AACR) ann

HiddenA line styled icon from Orion Icon Library.Eye